Key statistics
On Friday, Roche Holding AG (0TDF:LSE) closed at 59.21, -1.35% below its 52-week high of 60.02, set on Feb 17, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | -- |
|---|---|
| High | 59.21 |
| Low | 59.21 |
| Bid | -- |
| Offer | -- |
| Previous close | 59.34 |
| Average volume | 6.97k |
|---|---|
| Shares outstanding | 6.47bn |
| Free float | 341.17m |
| P/E (TTM) | 22.88 |
| Market cap | 386.33bn USD |
| EPS (TTM) | 2.59 USD |
| Annual div (ADY) | 1.59 USD |
|---|---|
| Annual div yield (ADY) | 2.69% |
| Div ex-date | Mar 28 2025 |
| Div pay-date | May 14 2025 |
| Next div ex-date | Mar 13 2026 |
| Next div pay-date | Jun 01 2026 |
Data delayed at least 15 minutes, as of Feb 20 2026 19:13 GMT.
More ▼
- FDA accepts New Drug Application for Roche’s giredestrant in ESR1-mutated, ER-positive advanced breast cancer
- Change to the Roche Enlarged Corporate Executive Committee
- Roche announces positive phase III results for Gazyva/Gazyvaro in primary membranous nephropathy, marking a significant milestone in this autoimmune disease
- Roche’s fenebrutinib is the first investigational medicine in over a decade that reduces disability progression in primary progressive multiple sclerosis (PPMS)
- [Ad-hoc-Mitteilung gemäss Art. 53 KR] Roche erzielt starkes Jahresergebnis für 2025 mit Verkaufswachstum von 7%
- [Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong 2025 results with 7% sales growth
- [Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase II results for its dual GLP-1/GIP receptor agonist CT-388 in people living with obesity
- FDA approves Roche’s Lunsumio VELO™ for subcutaneous use in relapsed or refractory follicular lymphoma
- Roche expands automated mass spectrometry menu with antibiotics drug monitoring CE mark approval offering industry’s broadest in vitro diagnostic menu
- Roche’s giredestrant reduced risk of invasive disease recurrence or death by 30% in ER-positive early-stage breast cancer
More ▼
